StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) says it is carefully evaluating the FDA’s drug‑safety communication on its GLP‑1 RA and will respond promptly

ORIGINAL · NewsquawkEli Lilly (LLY) says it is carefully evaluating the FDA’s drug‑safety communication on its GLP‑1 RA and will respond promptly
StockNow breaking-news AI analysis

Eli Lilly says it is evaluating an FDA drug-safety communication concerning its GLP-1 RA and will respond promptly; the item supplies no further details.

1 stocks
LLYEli Lilly & Co.$1,421.07Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Nvidia (NVDA) CEO's relationship with Alice Huang dated back to at least 2023 and facillitated the sale of at least USD 7.5bln in Nvidia chips to China, The Information reports citing sources

NVDAGeopolitics

An Iranian diplomatic source denies reports of an agreement with the US on uranium enrichment at 3.67% or other nuclear issues, insisting Tehran's two-day proposal remains unchanged and no detailed nuclear discussions have taken place, according to Avash

Geopolitics

Iranian Foreign Minister Araghchi says there are no plans for a meeting between Supreme National Security Council chief Mohsen Rezaei and US Vice President Vance, Al Mayadeen reports